Literature DB >> 9126094

Which patients with prostatic carcinoma require a staging bone scan?

P M Kemp1, G A Maguire, N J Bird.   

Abstract

OBJECTIVE: To determine whether the level of prostate-specific antigen (PSA) can be used to decide which patients with newly diagnosed prostatic carcinoma require a staging bone scan. PATIENTS AND METHODS: Of patients referred during an 18-month period for a staging bone scan, 98 (median age 72 years, range 52-89) had had their serum PSA level determined within 4 weeks of the bone scan and were assessed retrospectively for the presence of bony metastases.
RESULTS: Of the 98 patients, 26 who had bone scans showing bony metastases had a PSA level > 40 ng/mL. Reviewing the other published studies showed that in those newly diagnosed patients with a PSA level of < 20 ng/mL, the probability of having bony metastases detected on a bone scan was < 1%.
CONCLUSIONS: A staging bone scan can be omitted in the vast majority of patients with newly diagnosed prostatic carcinoma and a PSA level < 20 ng/mL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126094     DOI: 10.1046/j.1464-410x.1997.00121.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  9 in total

1.  [Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis].

Authors:  T Klatte; D Klatte; M Böhm; E P Allhoff
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

Review 2.  Prostate cancer in the elderly.

Authors:  Hatzimouratidis Konstantinos
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Imaging in the diagnosis and management of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2004

4.  Saudi Oncology Society clinical management guidelines for prostate cancer.

Authors:  Ashraf J Abusamra; Shouki Bazarbashi; Yasser Bahader; Hussain Kushi; Danny Rabah; Dany Rabbah; Naser Al Bogami; Khalid Al Ghamdi; Abdullah Al Ghamdi; Khaled Balaraj; Raouf Seyam; Mohammed Al Otaibi; Eyad Al Saeed
Journal:  Urol Ann       Date:  2011-03

5.  Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Authors:  Sultan Alkhateeb; Ashraf Abusamra; Danny Rabah; Mohammed Alotaibi; Rana Mahmood; Mubarak Almansour; Esam Murshid; Abdullah Alsharm; Ashwaq Alolayan; Imran Ahmad; Hussain Alkushi; Abdullah Alghamdi; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2014-10

6.  Prostate-specific antigen cutoff value for ordering sodium fluoride positron emission tomography/computed tomography bone scan in patients with prostate cancer.

Authors:  Ismet Sarikaya; Ali Sarikaya; Abdelhamid H Elgazzar; Vuslat Yurut Caloglu; Prem Sharma; Ali Baqer; Murat Caloglu; Mahmoud Alfeeli
Journal:  World J Nucl Med       Date:  2018 Oct-Dec

7.  Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy.

Authors:  Koramadai Karuppusamy Kamaleshwaran; Bhagwant Rai Mittal; Chidambaram Natrajan Balasubramanian Harisankar; Anish Bhattacharya; Shrawan Kumar Singh; Arup K Mandal
Journal:  Indian J Nucl Med       Date:  2012-04

Review 8.  Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Authors:  Ashraf Abusamra; Esam Murshid; Hussain Kushi; Sultan Alkhateeb; Mubarak Al-Mansour; Ahmad Saadeddin; Danny Rabah; Shouki Bazarbashi; Mohammed Alotaibi; Abdullah Alghamdi; Khalid Alghamdi; Abdullah Alsharm; Imran Ahmad
Journal:  Urol Ann       Date:  2016 Apr-Jun

Review 9.  Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017.

Authors:  Ali Aljubran; Ashraf Abusamra; Sultan Alkhateeb; Mohammed Alotaibi; Danny Rabah; Shouki Bazarbashi; Hussain Alkushi; Mubarak Al-Mansour; Hulayel Alharbi; Amin Eltijani; Abdullah Alghamdi; Abdullah Alsharm; Imran Ahmad; Esam Murshid
Journal:  Urol Ann       Date:  2018 Apr-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.